Trans women—individuals assigned female at birth who identify as female—often experience changes in erectile function during their transition journey, particularly when undergoing gender-affirming hormone therapy. Whether these changes constitute erectile dysfunction depends on individual goals and expectations. Some trans women wish to preserve erectile capacity, whilst others view reduced function as an affirming aspect of transition. Understanding how hormone therapy affects erectile function, what factors contribute to changes, and what support options exist empowers trans women to make informed decisions about their sexual health and wellbeing throughout their transition.
Summary: Trans women commonly experience changes in erectile function during hormone therapy, though whether this constitutes dysfunction depends on individual transition goals and expectations.
- Gender-affirming hormone therapy (oestrogen plus anti-androgens) suppresses testosterone, which typically reduces spontaneous erections and erectile rigidity.
- PDE5 inhibitors such as sildenafil may help maintain erectile function in trans women who wish to preserve it, though individual responses vary.
- Psychological factors, vascular health, other medications, and age all influence erectile function independently of hormone therapy.
- Sudden changes in erectile function warrant GP assessment to exclude cardiovascular disease or medication interactions.
- Trans women considering fertility preservation should discuss sperm banking before or very early in hormone therapy.
- NHS care for sexual health concerns is delivered through GPs, specialist gender identity clinics, and urology services using shared-care arrangements.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Understanding Erectile Function in Trans Women
Erectile function in trans women is a complex topic that intersects gender-affirming care, sexual health, and overall wellbeing. Trans women—individuals assigned male at birth who identify as female—may experience changes in erectile function as part of their transition journey, particularly when undergoing hormone therapy. It is important to recognise that erectile function can vary significantly among trans women, influenced by individual physiology, treatment choices, and personal preferences regarding genital function.
Erectile dysfunction (ED) is defined as the persistent difficulty in achieving or maintaining an erection sufficient for satisfactory sexual activity. Erectile function relies on a coordinated interplay of psychological arousal, neurological signals, vascular health, and hormonal balance. In cisgender men, testosterone plays a key role in maintaining libido and supporting the physiological mechanisms required for erections. For trans women, gender-affirming hormone therapy typically involves suppressing testosterone and introducing oestrogen, which fundamentally alters this hormonal landscape.
Whether changes in erectile function constitute "dysfunction" depends largely on individual goals and expectations. Some trans women may wish to preserve erectile capacity for sexual activity or future surgical options, whilst others may view reduced erectile function as an affirming aspect of their transition. There is no single "normal" experience—what matters is whether the individual's sexual function aligns with their personal needs and wellbeing.
Healthcare professionals should approach this topic with sensitivity, recognising that discussions about genital function require a non-judgemental, patient-centred approach. Care is typically delivered through shared-care arrangements between GPs and specialist gender identity clinics, following NHS England service specifications for adult gender dysphoria services. Understanding each trans woman's unique goals allows for tailored support and appropriate medical guidance throughout their transition journey.
How Hormone Therapy Affects Erectile Function
Gender-affirming hormone therapy (GAHT) for trans women typically consists of oestrogen (often oestradiol) combined with an anti-androgen medication such as cyproterone acetate or GnRH analogues. Spironolactone is sometimes used as an anti-androgen, though this is an off-label use in the UK and should only be prescribed under specialist guidance. This combination works to suppress testosterone production and introduce feminising effects including breast development, fat redistribution, and softer skin. However, these hormonal changes also significantly impact erectile function.
Testosterone suppression is the primary mechanism affecting erections. Testosterone supports nitric oxide production and vascular health in penile tissue, both essential for achieving and maintaining erections. When testosterone levels are suppressed to within typical female reference ranges, many trans women experience reduced spontaneous erections, decreased rigidity, and longer time required for arousal. Target testosterone levels vary by laboratory and individual gender identity clinic protocols, so treatment should follow local reference ranges and clinic-specific targets rather than a single threshold. Some may find erections difficult or impossible to achieve without specific stimulation or assistance.
The degree of change varies considerably between individuals. Factors influencing this include the specific medications used, dosage, duration of therapy, baseline vascular health, and psychological factors. Oestrogen alone can reduce erectile function, but when combined with anti-androgens, the effect is typically more pronounced. Some trans women notice changes within weeks of starting therapy, whilst others experience a more gradual decline over months.
It is worth noting that reduced erectile function does not necessarily mean reduced sexual pleasure or satisfaction. Many trans women report continued capacity for orgasm and sexual enjoyment, even when erectile function has diminished. The relationship between genital function and sexual wellbeing is highly individual and may evolve throughout transition. Regular monitoring of hormone levels by an endocrinologist or gender specialist, often through shared-care arrangements with GPs, helps ensure therapy remains both effective and safe.
Important safety note: If cyproterone acetate is prescribed, patients should be aware of the MHRA 2020 safety update regarding a small increased risk of meningioma (a usually benign brain tumour) with long-term use. The lowest effective dose should be used, and any new or worsening headaches, vision changes, or seizures should be reported immediately to a doctor.
Factors Contributing to Erectile Changes
Beyond hormone therapy, multiple factors can influence erectile function in trans women. Understanding these contributors helps distinguish expected treatment effects from potentially modifiable issues requiring clinical attention.
Psychological factors play a substantial role. Gender dysphoria—distress related to incongruence between assigned sex and gender identity—may affect sexual function both before and during transition. Some trans women experience reduced interest in genital-focused sexual activity due to dysphoria, whilst others may find that alleviating dysphoria through transition improves overall sexual wellbeing. Mental health conditions including depression and anxiety, which occur at higher rates in transgender populations, can independently affect libido and erectile function.
Vascular and metabolic health remains important. Conditions such as diabetes, hypertension, high cholesterol, and cardiovascular disease impair blood flow necessary for erections. Trans women with these conditions may experience more pronounced erectile changes. NICE guidance recommends that all individuals presenting with erectile dysfunction should have their cardiovascular risk factors assessed, including blood pressure, lipid profile, and HbA1c where appropriate. Smoking significantly worsens vascular health and should be addressed as part of holistic care.
Medications beyond hormone therapy can contribute to erectile difficulties. Antidepressants (particularly SSRIs), antihypertensives, antipsychotics, 5-alpha-reductase inhibitors, opioids, and certain other medications commonly affect sexual function. A medication review with a GP or specialist can identify potentially modifiable contributors. The British National Formulary (BNF) provides detailed information on medicines associated with sexual dysfunction.
Tissue changes may occur with prolonged hormone therapy, though evidence specific to trans women is limited and largely extrapolated from other populations. This consideration is particularly relevant for trans women who may wish to preserve erectile capacity or are considering vaginoplasty, as some surgical techniques utilise penile tissue.
Age and general health influence erectile function in all populations. Trans women face the same age-related changes affecting vascular and neurological health as any individual, which may compound hormone-related effects.
Managing Erectile Function: Options and Support
For trans women who wish to maintain or improve erectile function, several evidence-based options exist. The appropriateness of each approach depends on individual circumstances, transition goals, and overall health status.
Phosphodiesterase-5 (PDE5) inhibitors such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil are commonly used to support erectile function. These medications work by enhancing blood flow to penile tissue in response to sexual stimulation. Limited evidence suggests they may help some trans women on hormone therapy, though individual responses vary. Generic sildenafil is generally available on NHS prescription when clinically appropriate. Other PDE5 inhibitors may be subject to Selected List Scheme (SLS) restrictions, and local integrated care board (ICB) formularies may guide first-line choice. Sildenafil 50 mg (Viagra Connect) is also available to purchase from pharmacies following a consultation to ensure it is safe and appropriate.
Important safety information: PDE5 inhibitors are contraindicated in individuals taking nitrates (for angina) or riociguat (for pulmonary hypertension) due to the risk of severe hypotension. Caution is required in those taking alpha-blockers or with significant cardiovascular disease. Common side effects include headache, flushing, indigestion, nasal congestion, and visual disturbances. Full prescribing information is available in the BNF and individual Summary of Product Characteristics (SmPC) documents via the electronic Medicines Compendium (EMC). Any suspected side effects should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.
Adjusting hormone therapy may be considered in consultation with a gender specialist. Some trans women opt for lower anti-androgen doses or modified regimens that allow slightly higher testosterone levels whilst still achieving feminisation. This approach requires careful balancing of transition goals against sexual function priorities and should only be undertaken with specialist guidance.
Alprostadil (a prostaglandin) is a second-line option available as intracavernosal injection, intraurethral pellet, or topical cream. It works by directly dilating blood vessels in the penis. This option requires training and careful use but can be effective when PDE5 inhibitors are unsuitable or ineffective.
Vacuum erection devices provide a non-pharmacological option, using negative pressure to draw blood into the penis. Whilst less convenient than oral medications, they can be effective for achieving erections sufficient for sexual activity and are available on NHS prescription.
Psychological support through counselling or sex therapy can address emotional and relational aspects of sexual function changes. Many trans women benefit from exploring new ways of experiencing sexual pleasure that may not centre on penetrative activity or erections. GPs can refer to NHS psychosexual services where available.
If first-line treatments are ineffective, GPs can refer to urology, andrology, or specialist erectile dysfunction services for further assessment and management options.
When to Seek Medical Advice
Trans women should feel empowered to discuss erectile function and sexual health with their healthcare providers. Several situations warrant medical consultation:
Sudden or unexpected changes in erectile function, particularly if occurring outside the context of recent hormone therapy adjustments, should be evaluated. Whilst gradual changes are expected with GAHT, abrupt loss of function could indicate cardiovascular issues, medication interactions, or other health concerns requiring investigation. New-onset erectile dysfunction may be an early marker of cardiovascular disease, and a GP assessment of cardiovascular risk factors is recommended.
Emergency situation: If an erection lasts longer than four hours (priapism), seek immediate medical attention at an emergency department. This is a medical emergency that requires urgent treatment to prevent permanent damage, and the risk may be higher in individuals using alprostadil or other vasoactive agents.
Distress or relationship difficulties related to sexual function changes merit support. GPs can provide referrals to psychosexual services, counselling, or specialist gender identity clinics. Sexual wellbeing is an important component of overall health and quality of life.
Before starting PDE5 inhibitors, consultation with a GP is essential. These medications interact with certain heart medications (particularly nitrates and riociguat) and may not be suitable for individuals with specific cardiovascular conditions or taking alpha-blockers. A proper assessment ensures safe prescribing.
If considering fertility preservation, early discussion is crucial. Hormone therapy typically reduces sperm production, and prolonged treatment may make fertility preservation more difficult. Trans women wishing to have biological children should discuss sperm banking before or very early in hormone therapy. The Human Fertilisation and Embryology Authority (HFEA) provides detailed patient information on sperm freezing and storage options.
Persistent pain, unusual discharge, or skin changes affecting genital tissue require prompt medical assessment to rule out infection or other pathology.
When planning gender-affirming surgery, discussing erectile function with the surgical team is important. Some vaginoplasty techniques may benefit from preserved penile tissue elasticity, and surgeons can provide specific guidance on pre-operative preparation.
Healthcare providers should create an environment where trans women feel comfortable discussing sexual health without fear of judgement. NHS England service specifications for adult gender dysphoria clinics emphasise the importance of holistic, patient-centred care for transgender individuals, including addressing sexual health needs as part of comprehensive gender-affirming care. Trans women experiencing difficulties accessing appropriate support should consider contacting specialist gender identity clinics or transgender health organisations for guidance on navigating NHS services.
UK referral pathways typically involve initial GP assessment, including cardiovascular risk evaluation and medication review. GPs may prescribe first-line treatments or refer to urology, andrology, psychosexual services, or gender identity clinics as appropriate. Further information is available from NICE Clinical Knowledge Summaries on erectile dysfunction and NHS.uk patient information pages.
Frequently Asked Questions
Do trans women on hormone therapy experience erectile dysfunction?
Many trans women on hormone therapy experience reduced erectile function due to testosterone suppression, though the degree varies considerably between individuals. Whether this constitutes dysfunction depends on personal transition goals—some trans women wish to preserve erectile capacity whilst others view reduced function as affirming.
Can trans women still have orgasms if they lose erectile function?
Yes, many trans women report continued capacity for orgasm and sexual pleasure even when erectile function has diminished. Sexual satisfaction does not depend solely on erections, and the relationship between genital function and sexual wellbeing is highly individual and may evolve throughout transition.
Will Viagra work for trans women taking oestrogen?
Sildenafil (Viagra) and other PDE5 inhibitors may help some trans women on hormone therapy maintain erectile function, though individual responses vary. A GP consultation is essential before starting these medications to ensure they are safe, particularly if you have cardiovascular conditions or take nitrates or alpha-blockers.
How quickly does hormone therapy affect erections in trans women?
Some trans women notice changes in erectile function within weeks of starting gender-affirming hormone therapy, whilst others experience a more gradual decline over months. The timeline varies depending on medication type, dosage, individual physiology, and baseline testosterone levels.
Should I talk to my GP about erectile changes during transition?
Yes, discussing erectile function with your GP is important, especially if changes cause distress or occur suddenly outside hormone therapy adjustments. Your GP can assess cardiovascular risk factors, review medications, prescribe treatments like sildenafil if appropriate, or refer you to specialist services including urology or psychosexual support.
Can I preserve fertility if hormone therapy affects my erectile function?
Hormone therapy typically reduces sperm production, and prolonged treatment may make fertility preservation more difficult. Trans women wishing to have biological children should discuss sperm banking with their GP or gender clinic before starting or very early in hormone therapy, as this offers the best chance of successful preservation.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
